Introduction {#Sec1}
============

In 2015, coronary artery disease (CAD) was the leading cause of death worldwide \[[@CR1]\] and, although many patients now survive acute myocardial infarction (AMI), a significant proportion are left with angina pectoris \[[@CR2]\]. Indeed, angina due to CAD affects around 112 million people worldwide \[[@CR3]\]. Although annual mortality from angina is relatively low \[[@CR4], [@CR5]\], symptoms are often disabling and adversely affect patient quality of life. In a global study, the highest rates of CAD disability were found in Eastern Europe and Central Asia, and stable angina made the largest contribution to CAD disability, with smaller contributions from ischemic heart failure and nonfatal AMI \[[@CR6]\]. Angina also has a significant impact on healthcare costs, and it has been demonstrated that, following acute coronary syndrome, healthcare resource utilization in patients with angina is double that of patients without symptoms \[[@CR7]\].

The treatment of patients with stable angina is focused primarily on relief of symptoms, improvement of quality of life, and prevention of cardiovascular (CV) events \[[@CR8]\]. HR reduction is an integral part of antianginal therapy; the target rate is below 60 bpm \[[@CR8], [@CR9]\] and BB, calcium channel blockers, and ivabradine are recommended to reduce HR and symptoms \[[@CR8]\]. Data from the large international CLARIFY registry demonstrated that despite high BB usage, patients with stable angina often had a resting HR greater than 70 bpm, and this was associated with more frequent angina and ischemia \[[@CR10]\]. This may be related, in part, to failure to increase doses of BBs and discontinuation of therapy \[[@CR11]\], and there is a clear need for further lowering of HR in many patients with stable angina.

Ivabradine is the first selective inhibitor of the cardiac pacemaker *I*~f~ current that controls spontaneous diastolic depolarization in the sinus node and reduces HR \[[@CR12]\]. It is indicated for the symptomatic treatment of chronic stable angina in adults with CAD with normal sinus rhythm and HR of at least 70 bpm as well as for management of chronic heart failure patients.

Ivabradine improves coronary blood flow through different mechanisms compared with BBs and this raises the opportunity for combination treatment in patients who remain symptomatic with BB therapy alone. In a small study of patients with stable angina, combination treatment with ivabradine and bisoprolol reduced angina symptoms and improved exercise capacity compared with an increased dose of bisoprolol \[[@CR13]\]. In the larger placebo controlled ASSOCIATE study, addition of ivabradine to atenolol treatment resulted in significant improvements in exercise capacity in patients with stable angina \[[@CR14]\].

To improve our understanding about the broader potential for combination treatment with ivabradine and BBs, we initiated the CONTROL-2 study in a large population of patients in Russia with stable angina on submaximal doses of BBs. The study compared the effects of adding ivabradine to BBs versus uptitration of BBs on HR, angina attacks, nitroglycerin use, and patient health status. The research has been previously published in Russian \[[@CR15]\].

Methods {#Sec2}
=======

The CONTROL-2 study was a multicenter, open, randomized, prospective study with the inclusion of consecutive patients. A total of 389 doctors from 72 cities of the Russian Federation (RF) participated in the study, including cardiologists (232; 60.6%), general practitioners (GPs) (121; 31.6%), and internal medicine physicians (30; 7.8%).

Study participants were adult patients (≥ 18 years) with documented angina of effort, CCS class II--III, which had been stable for at least 3 months, with at least three attacks per week. Patients were in sinus rhythm with HR of at least 60 bpm and were undergoing regular treatment of stable angina with a BB in a dose which was below the maximum for angina treatment. Exclusion criteria included chronic heart failure of NYHA class III--IV, non-sinus rhythm, blood pressure greater than 180/100 mmHg at rest, and treatment with verapamil or diltiazem.

The study design is outlined in Fig. [1](#Fig1){ref-type="fig"}. Consecutive patients were allocated to standard therapy with BB uptitration to the maximal tolerated dose or ivabradine was added to their current BB dose, in a 1:4 ratio of patients. This treatment allocation ratio was used to increase the chance of detecting any tolerability problems related to combination of ivabradine with BB. Uptitration of BB was carried out according to achieved resting HR and tolerability as, in contrast to heart failure, there is no recommended target dose or recommended BB molecule in treating stable angina, and thus a wide variety of agents and doses are commonly used: atenolol 25--100 mg/day \[[@CR16]\], bisoprolol 2.5--10 mg/day \[[@CR16], [@CR17]\], betaxolol 5--20 mg/day \[[@CR16]\], carvedilol 6.25--100 mg/day \[[@CR16]\], nebivolol 2.5--5 mg/day \[[@CR16], [@CR17]\], metoprolol 50--200 mg/day \[[@CR16], [@CR17]\], and propranolol 40--320 mg/day \[[@CR16]\].Fig. 1Design of the CONTROL-2 study

Five clinic visits were performed: at baseline (visit 0), at 2 weeks (visit 1), at 4 weeks (visit 2), at 8 weeks (visit 3), and finally at 16 weeks (visit 4).

Clinical outcomes were change in HR during the 16-week treatment period, change in CCS class of angina, number of angina attacks with standard therapy vs. ivabradine, proportion of patients who were angina-free between study visits, and patient self-reported health status (visual analog scale, VAS). The quantitative parameters are presented as the mean arithmetic value and standard deviation, if values were normally distributed, or as the median with 25th and 75th percentiles, if values were not normally distributed. Differences in the quantitative variables between groups were analyzed using a Student's *t* test for independent samples with parametric distribution of values, or the Mann--Whitney test when samples demonstrated non-parametric distribution. Changes in the quantitative variables during the treatment were analyzed using a Student's *t* test for paired samples or a Wilcoxon test for nonparametric parameters. Differences in the categorical variables between the groups were analyzed using a Pearson's Chi squared test with Yates' correction. Changes in the categorical variables during treatment were analyzed using a McNemar's test. Differences were considered as statistically significant at *p* \< 0.05.

Compliance with Ethics Guidelines {#Sec3}
---------------------------------

All procedures complied with the ethical standards of the responsible committee on human experimentation (institutional and national), the 1964 Declaration of Helsinki, as revised in 2013, and the European Independent Ethics Committee. The CONTROL-2 protocol was approved by the Ethical Review Committee of the Moscow State University of Medicine and Dentistry (no. 18/2 dd. 22/09/2009; Moscow). Informed consent was obtained from all individual participants included in the study.

The study has been registered at ISRCTN registry with study ID ISRCTN30654443.

Results {#Sec4}
=======

During the period from November 2009 to April 2010, 1104 patients were enrolled into the study (BB uptitration: 228 patients, 20.7%; ivabradine + BB: 876 patients, 79.3%). Baseline characteristics did not differ significantly between the two groups, except for HR which was significantly higher in the ivabradine + BB group (Table [1](#Tab1){ref-type="table"}). The most frequently used BBs were bisoprolol and metoprolol (Fig. [2](#Fig2){ref-type="fig"}). Both groups, received adequate doses of standard therapy with angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) (\> 80%), statins (75%), and antiplatelet therapy (\> 90%) (Table [2](#Tab2){ref-type="table"}). At baseline, no patients had achieved maximal doses of BB, though a higher proportion of patients in the ivabradine + BB group were prescribed BBs at 50% or more of the recommended maximal dose than those in the BB uptitration group (55% vs. 45%) (Fig. [3](#Fig3){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). At the end of the study (week 16), treatment with BB was reported in 227 (99.6%) of patients in the BB uptitration group and 863 (98.5%) of patients in the ivabradine + BB group (*p* = 0.323). Forty-five percent of patients had achieved the maximal therapeutic BB dosage in the BB uptitration group but, as might be expected, there was little change in BB dose in patients taking ivabradine + BB (Fig. [3](#Fig3){ref-type="fig"}). The rates of administration of individual BBs by the end of the study were similar in both groups, but the doses were significantly different. By the end of the study, the daily dose of ivabradine was 5 mg (bid) in 220 (25.2%) patients and 7.5 mg (bid) in 654 (74.8%) patients.Table 1Baseline characteristics of patients in the CONTROL-2 study (*n* = 1075)ParameterStandard therapy group, *n* = 228Ivabradine group, *n* = 876*p* valueDemographic parameters  Age, years61.2 ± 9.360.0 ± 9.60.097  ≥ 65 years, *n* (%)70 (31.5)248 (29.6)0.633  Female, *n* (%)105 (46.1)437 (49.9)0.339  BMI, kg/m^2^28.9 ± 4.428.7 ± 5.10.603  BMI ≥ 30 kg/m^2^, *n* (%)76 (33.3)275 (31.4)0.638Medical history  Hypertension, *n* (%)202 (88.6)745 (85.0)0.207  Previous MI, *n* (%)91 (39.9)320 (36.5)0.387  Previous CABG, *n* (%)18 (7.9)41 (4.7)0.079  Previous PCI, *n* (%)15 (6.6)38 (4.3)0.216  CHF, class I/II NYHA, *n* (%)56 (24.6)/107 (46.9)163 (18.6)/412 (47.0)0.078  Diabetes mellitus34 (14.9)130 (14.8)1.000  Peripheral artery disease, *n* (%)28 (12.3)107 (12.2)1.000  Stroke or TIA, *n* (%)16 (7.0)37 (4.2)0.113  Asthma, *n* (%)2 (0.9)17 (1.9)0.394  COPD, *n* (%)19 (8.3)89 (10.2)0.483  Depression, *n* (%)17 (7.5)80 (9.1)0.506  Erectile dysfunction, *n* (%)24 (19.5)87 (19.8)1.000Clinical findings  Number of angina attacks per week7 (4; 12)7 (4; 10)0.818  Number of nitroglycerin tablets per week7 (4; 11)7 (4; 10)0.846  Angina of class III, *n* (%)67 (29.5)279 (31.9)0.538  SBP, mmHg144.9 ± 15.6143.0 ± 17.50.115  DBP, mmHg86.8 ± 8.686.5 ± 8.90.409  HR, bmp83.2 ± 10.985.1 ± 10.40.015  LVEF, %55.3 ± 7.756.0 ± 8.40.588  Coronary angiography, *n* (%)48 (21.1)139 (15.9)0.078  Positive stress echo test, *n* (%)10 (4.4)48 (5.5)0.622  Positive exercise tolerance test, *n* (%)123 (53.9)480 (54.8)0.877Data presented as mean ± standard deviation, or mean (25th; 75th percentiles)*BMI* body mass index, *bpm* beats per minute, *LVEF* left ventricular ejection fraction, *CABG* coronary artery bypass grafting, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *PCI* percutaneous coronary intervention, *CHF* chronic heart failure, *MI* myocardial infarction, *TIA* transient ischemic attack, *COPD* chronic obstructive pulmonary disease Fig. 2Beta-blocker treatment at baseline Table 2Treatment prior to study inclusionTreatmentsPrescription rate, *n* (%)*p* valueStandard therapy group, *n* = 228Ivabradine group, *n* = 876Aspirin or other antiplatelet drugs210 (92.1)811 (92.6)0.919Long-acting nitrates110 (48.2)443 (50.6)0.582Lipid lowering drugs169 (74.1)655 (74.8)0.908Calcium channel blockers39 (17.1)149 (17.0)1.000Angiotensin converting enzyme inhibitors161 (70.6)639 (72.9)0.536Angiotensin II receptor antagonists26 (11.4)84 (9.6)0.490Thiazide diuretics45 (19.7)130 (14.8)0.089Trimetazidine36 (15.8)123 (14.0)0.573 Fig. 3Change in beta-blocker dosages in the study in BB uptitration group (**a**) and in BB + ivabradine group (**b**) Table 3Change in beta-blocker dosages in the studyRange of dosages of BBBaseline, *N* (%)*p* valueStudy end, *N* (%)*p* valueStandard therapy, *n* = 228Ivabradine, *n* = 876Standard therapy, *n* = 228Ivabradine, *n* = 876≥ 50% of maximal dosage (but less than maximal dosage)102 (44.7)481 (54.9)0.00895 (41.6)453 (52.6)0.001Maximal dosage----103 (45.1)24 (2.8)0.005\< 50% of maximal dosage126 (55.3)395 (45.1)0.02830 (13.1)385 (44.6)0.001

HR was reduced substantially in both groups from 83.2 ± 10.9 to 63 ± 8 bpm in the BB uptitration group and from 85.1 ± 10.4 to 61 ± 6 bmp in the ivabradine + BB group (Fig. [4](#Fig4){ref-type="fig"}). In both groups, the target HR (55--60 bpm) was achieved in approximately half of the patients with stable angina.Fig. 4Change in HR during the 16-week treatment period

Comparable reductions in blood pressure were seen for the two groups, from 145/87 to 125/78 mmHg in the BB uptitration group and 143/87 to 126/78 mmHg in the ivabradine + BB group.

The optimization of treatment resulted in a substantial antianginal effect in both groups. However, by the end of 16-week treatment the proportion of patients with CCS class I angina was significantly higher in the ivabradine + BB group than with BB uptitration (37.1% vs. 28%, respectively; *p* = 0.017), while at the beginning of the study there were no patients with CCS class I angina in either group. The proportion of patients who were free of angina after week 8 and week 16 of the study was significantly greater with ivabradine + BB than with BB uptitration (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Proportion of patients free of angina in the period between visits

Analysis of patient diaries showed that there was a reduction in the rate of angina attacks and nitroglycerin consumption in both groups (Table [4](#Tab4){ref-type="table"}). However, by the end of the study, the need for nitroglycerin in the BB + ivabradine group was significantly lower: 1 (0; 2) vs. 2 (1; 3), *p* = 0.015 s. Patient health status, based on the results of the VAS, improved in both groups, from 67 (51; 78) to 41 (29; 65) in the BB uptitration group and from 65 (48; 78) to 32 (18; 47) in the ivabradine + BB group. This improvement was higher in the ivabradine + BB group than in the uptitration group (*p* = 0.001) (Fig. [6](#Fig6){ref-type="fig"}).Table 4Changes in angina attacks and SAN use (median (IQR))Number of angina attacks per weekSAN use per weekGroup 1 (standard therapy)Group 2 (addition of ivabradine)*p*Group 1 (standard therapy)Group 2 (addition of ivabradine)*p*Baseline5 (3; 7)4 (2; 8)0.314 (2; 8)4 (2; 8)0.71W23 (2; 6)3 (2; 5)0.833 (1; 5)2 (1; 5)0.67W42 (1; 5)2 (1; 5)0.752 (1; 5)2 (1; 4)0.05W82 (1; 4)2 (1; 3)0.872 (1; 3)1 (0; 3)0.06W162 (1; 4)2 (1; 3)0.332 (1; 3)1 (0; 2)0.01 Fig. 6Change in patient health status (VAS) with treatment

Adverse Events {#Sec5}
--------------

AEs were significantly more common in the BB uptitration than the ivabradine + BB group (18.4% vs. 9.4%, *p* \< 0.001) (Fig. [7](#Fig7){ref-type="fig"}). The rates of asthma, dyspnea, hypotension, and fatigue were all significantly higher in the BB uptitration group (Table [5](#Tab5){ref-type="table"}). Hospital admissions (for any reason) were reported more often in the standard therapy group \[6 cases (2.6%) vs. 8 cases (0.9%), *p* = 0.083\]. Death, nonfatal MI, or nonfatal stroke were reported in 3 (1.3%) and 2 (0.2%) cases, respectively (*p* = 0.063). HR less than 50 bmp was registered on at least one visit (1--4) in 7 patients: 1 (0.4%) from the BB uptitration group and 6 (0.7%) from the ivabradine + BB group (*p* = 1.000).Fig. 7Selected adverse events Table 5Adverse events, *n* (%)Group 1 (standard therapy)Group 2 (addition of ivabradine)*p* valuePhosphenes0 (0)10 (1.1)0.230Gastrointestinal (nausea, vomiting, epigastric pain, constipation)1 (0.4)8 (0.9)0.695Cough0 (0)5 (0.6)0.590Sexual dysfunction1 (0.4)2 (0.2)0.501Asthma, dyspnea3 (1.3)0 (0)0.009Bradycardia2 (0.9)11 (1.3)1.000Hypotension13 (5.7)8 (0.9)0.001Headache3 (1.3)7 (0.8)0.440Dizziness6 (2.6)10 (1.1)0.172Weakness8 (3.5)16 (1.8)0.195Fatigue3 (1.3)1 (0.1)0.030Seizures, pain in the muscles of the legs0 (0)1 (0.1)1.000Sleep disorders1 (0.4)1 (0.1)0.371

Discussion {#Sec6}
==========

In the CONTROL-2 trial, we found that combination treatment with ivabradine and BBs resulted in significantly more pronounced antianginal efficacy for patients than uptitration of BBs, with a higher proportion of patients becoming angina-free: half of the patients receiving combination therapy with ivabradine and BBs became angina-free, compared with approximately one-third of the patients receiving standard uptitration with BBs.

The addition of ivabradine to BB therapy was also better tolerated than uptitration of BBs, and the enhanced efficacy and tolerability were reflected in a greater improvement in patient health status in the ivabradine + BB group.

Factors which may have contributed to the superiority of combination treatment with ivabradine + BB over uptitration of BBs include the failure of over half of the patients in the uptitration group to reach maximal therapeutic doses of BB, and complementary effects of ivabradine on coronary flow. BBs act directly on the heart to reduce HR, also affecting myocardial contractility and atrioventricular conduction \[[@CR8]\]. They increase perfusion of ischemic areas by prolonging diastole and increasing vascular resistance in non-ischemic areas \[[@CR8]\] but also impair isovolumic ventricular relaxation and thus offset part of the benefit in terms of the diastolic pressure--time integral \[[@CR18]\]. Unlike BBs, ivabradine has no negative inotropic and lusitropic effects for a comparable reduction in HR, resulting in more prolonged diastolic duration than with BBs \[[@CR19]\]. In addition, ivabradine does not unmask alpha-adrenergic vasoconstriction and, unlike BBs, therefore maintains coronary dilatation during exercise \[[@CR19]\]. Compared to BBs, ivabradine also increases coronary flow reserve and collateral perfusion, promoting the development of coronary collaterals \[[@CR19]\]. There is also evidence from experimental and clinical studies that ivabradine may reduce myocardial ischemia and its consequences not only through HR reduction but also through additional pleiotropic mechanisms which could include attenuated formation of reactive oxygen species in cardiomyocyte mitochondria \[[@CR20]--[@CR22]\]. Some data from clinical studies also support some heart rate-independent benefit from ivabradine. For example the improved coronary flow velocity reserve was reported with ivabradine in patients with stable CAD when HR reduction was abrogated by atrial pacing \[[@CR23]\]. In another study in patients with stable CAD, ivabradine improved coronary flow velocity reserve to a significantly greater extent than bisoprolol despite the same HR reduction \[[@CR24]\]. Together, these additional properties of ivabradine may help to explain the beneficial antianginal effects of combination therapy with BBs compared with BB uptitration.

The advantages of combination treatment with ivabradine + BBs for patients with stable angina that we have seen in CONTROL-2 are supported by data from previous randomized studies \[[@CR13], [@CR14]\]. In a study of 24 patients with stable angina, comparable reductions in mean resting HR were seen after 2 months with ivabradine in combination with bisoprolol 5 mg vs. bisoprolol uptitrated from 5 to 10 mg. There was a significantly greater reduction in weekly number of angina attacks requiring sublingual nitrate consumption with combination therapy (*p* = 0.041) \[[@CR13]\]. In the ASSOCIATE study, addition of ivabradine (5--7.5 mg bid) to atenolol 50 mg od resulted in significant improvements in exercise capacity at 4 months, relative to placebo, in patients with stable angina pectoris receiving BB therapy \[[@CR25]\].

In the REDUCTION study carried out in everyday clinical practice, significant reductions in HR (*p* \< 0.0001) and angina episodes (*p* \< 0.0001) were seen at 4-month follow-up in a cohort of 344 patients treated with both ivabradine and BBs \[[@CR26]\]. Efficacy and tolerance were graded as "very good/good" for 96% and 99% of the patients treated \[[@CR26]\]. Further support for the ivabradine + BB combination approach in stable angina comes from pooled data from three large observational studies with a total of 8555 patients in which ivabradine therapy for 4 months was associated with a significant reduction in the frequency of angina attacks (*p* \< 0.0001) and consumption of short-acting nitrates (*p* \< 0.0001), irrespective of age, comorbidities, and BB use \[[@CR27]\]. HR was reduced by 16% during ivabradine treatment, and 85% of patients achieved an HR of less than 70 bpm or a reduction of at least 10 bpm. Improvements were also seen in clinical status and QoL \[[@CR27]\].

Clinical Implications {#Sec7}
---------------------

Given the potential for synergistic effects between BBs and ivabradine, the results of CONTROL-2 suggest that, in patients who remain symptomatic while taking BBs, combining ivabradine and BBs provides better efficacy than uptitrating the BB dose.

The data on better efficacy of the combination of ivabradine and BB support the rationale for a fixed-dose combination of ivabradine and metoprolol which is now available for use in clinical practice and could be beneficial in terms of adherence to treatment, which could further improve the antianginal effects of this combination therapy.

Limitations {#Sec8}
-----------

The HR threshold for entry into CONTROL-2 (≥ 60 bpm) was below the HR threshold of at least 70 bpm currently recommended for ivabradine treatment. However, as the population characteristics at baseline clearly show (Table [1](#Tab1){ref-type="table"}), all of the patients in the study had an HR greater than 70 bpm. Indeed, patients in the ivabradine + BB group had a significantly higher baseline HR than those in the BB uptitration group, owing to the open design of the study. Although randomization of patients in CONTROL-2 was not computer generated, the use of consecutive patient randomization in a 4:1 ratio for ivabradine + BB versus BB uptitration should have eliminated the potential for investigator bias, resulting in patients being assigned to study treatments according to perceived disease severity.

The proportion of patients who had undergone surgery/procedures for stable angina (coronary artery bypass grafting and percutaneous coronary intervention) was lower than would be expected in many European and US populations. In CONTROL-2, less than 8% of patients in the BB uptitration group and less than 5% of those on ivabradine + BB had had CABG, and less than 7% and less than 5%, respectively, had had PCI. This compared with 22% and 59% in the REDUCTION study carried out in Germany \[[@CR26]\]. However, the findings in CONTROL-2 are typical of practice in Russia, where access to such interventions is limited.

CONTROL-2 underlined the challenge of reducing HR and improving angina symptoms with BBs alone, and the difficulty of uptitration of BB owing to tolerability problems. Previous data from the CLARIFY registry in stable CAD showed that 41% of patients taking BB had a HR of at least 70 bpm, and only 22% of those with angina symptoms had an HR of 60 bpm or less \[[@CR9]\]. In a UK study of 500 patients undergoing PCI for chronic stable angina, 78% were receiving BBs, at a mean equivalent dose of bisoprolol of 3.1 mg \[[@CR28]\]---at the lower end of the recommended dose range \[[@CR16], [@CR17]\] In the CONTROL study in patients with stable angina, carried out previously, mean BB doses were also low (bisoprolol 5 mg, metoprolol 50 mg, nebivolol 5 mg) \[[@CR29]\].

Conclusions {#Sec9}
===========

In patients with stable angina, combination therapy with ivabradine and BBs demonstrated more pronounced clinical improvement in patient health status compared to BB uptitration. Treatment was well tolerated and effectively addressed the current failure to optimize angina and HR control with BBs alone owing, at least in part, to inability to reach satisfactory doses.
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